Sanofi-Aventis Intends to Contest in Court the Decision to Classify Acomplia Among Non-reimbursable Drugs in GermanyPARIS, January 12, 2007 - The German Ministry of Health has ratified the recommendation of the German Federal Joint Committee (“Geme insamer Bundesausschuss” – “G-BA”) to classify Acomplia® (rimonabant) among non reimbursable drugs, or “comfort” drugs (Section 34 of the Social Code Volume V).
The decision has been published in the Official Journal of the Government (Bundesanzeiger). Sanofi-aventis considers the proposed reimbursement classification of Acomplia® as unjustified given the profile of the drug.
Sanofi-aventis intends to contest in court the classification of Acomplia® under Section 34.
Sanofi-aventis is one of the world’s leading pharmaceutical companies. Backed by a worldclass R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous
system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in
sanofi -aventis’ annual report on Form 20-F for the year ended December 31, 2005. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.
Posted: January 2007
Recommended for you